Outcome of a Single Intravitreal Bevacizumab Injection on the Visual Acuity and Course of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy
- PMID: 24074489
- DOI: 10.3109/02713683.2013.833247
Outcome of a Single Intravitreal Bevacizumab Injection on the Visual Acuity and Course of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy
Abstract
Abstract Purpose: To evaluate the effect of a single intravitreal 1.25 mg/0.05 ml bevacizumab (IVB) (Avastin, Genentech) injection on the visual outcome and both intraoperative and postoperative course of pars plana vitrectomy (PPV) in proliferative diabetic retinopathy. Study Design: Prospective case-control interventional comparative study. Methods: One hundred patients (100 eyes) were divided into two groups: Group I had undergone PPV with preoperactive IVB (50 patients), and Group II had undergone PPV without IVB (50 patients). Best corrected visual acuity (BCVA), intraoperative and postoperative complications were compared between both groups. Patients were followed-up for one year. Results: After one year, there was a highly statistically significant difference in the mean BCVA, as it was (0.146 ± 0.103) in Group I and 0.069 ± 0.049 in Group II with (p < 0.001), while mean bleeding frequency in Group I was 0.7 ± 0.78 times/case with range between 0 and 2 bleeding attacks/case and mean bleeding frequency in Group II was 3.12 ± 1.31times/case with range between 3 and 6 bleeding attacks/case and the difference was statistically significant as (p < 0.001). Diathermy was used in Group I in 15 patients only with mean frequency of 0.3 ± 0.46 times/case with range between 0 and 1 attack/case; while diathermy was used in all cases in Group II with mean frequency of 2.4 ± 1.06 times/case with range between 1 to 4 times/case and this difference was also statistically significant as p < 0.001. Postoperative vitreous hemorrhage developed in 3 eyes (6%) in Group I and 15 eyes (30%) in Group II and this difference was statistically significant (p < 0.003). All the other intraoperative and postoperative complications were reduced in Group I, but with no statistically significant difference between both groups. Conclusions: The use of intravitreal bevacizumab before pars plana vitrectomy is beneficial in improving visual outcome, minimizing the incidence of intraoperative bleeding and reducing the need for intraoperative diathermy.
Similar articles
-
Effect of Bevacizumab Injection before Vitrectomy on Intravitreal Hemorrhage in Pseudophakic Patients with Proliferative Diabetic Retinopathy.Ophthalmol Eye Dis. 2013 Jul 15;5:11-5. doi: 10.4137/OED.S12352. Print 2013. Ophthalmol Eye Dis. 2013. PMID: 23926440 Free PMC article.
-
Intravitreal Avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy.Pak J Med Sci. 2013 Apr;29(2):590-2. doi: 10.12669/pjms.292.3044. Pak J Med Sci. 2013. PMID: 24353583 Free PMC article.
-
Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):641-50. doi: 10.1007/s00417-009-1247-7. Epub 2009 Dec 12. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20012643
-
Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy.Int J Ophthalmol. 2010;3(3):261-3. doi: 10.3980/j.issn.2222-3959.2010.03.19. Epub 2010 Sep 18. Int J Ophthalmol. 2010. PMID: 22553568 Free PMC article.
-
A Systematic Review and Meta-Analysis of Clinical Outcomes of Small Gauge Vitrectomy with or without Intravitreal Anti-Vascular Endothelial Growth Factor Agents Pretreatment for Proliferative Diabetic Retinopathy.Ophthalmic Res. 2023;66(1):777-790. doi: 10.1159/000530231. Epub 2023 Mar 27. Ophthalmic Res. 2023. PMID: 36972566
Cited by
-
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4. Cochrane Database Syst Rev. 2023. PMID: 37260074 Free PMC article. Review.
-
Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2015 Aug 7;2015(8):CD008214. doi: 10.1002/14651858.CD008214.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 May 31;5:CD008214. doi: 10.1002/14651858.CD008214.pub4. PMID: 26250103 Free PMC article. Updated.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous